This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind Corporation Pending FDA Approval Inspires Analyst Report By BrokerBank Securities, Inc.

NEW YORK, May 14, 2014 /PRNewswire/ -- MannKind Corporation (NASDAQ: MNKD) In the U.S. alone, roughly 1 of 12 people are managing diabetes. China has approximately 100 million diabetic patients as of 2012 statistics. Total global insulin sales have grown an average of $4 billion a year between 2011 and 2012 ( $16.8B in 2011 and $20.8B in 2012). However, in 2013, sharp price increases sent the total market up to $35 billion. By 2018, total insulin sales are expected to increase 66% to reach more than $58 billion due to continued increase in price and patients.

MannKind has developed a product called AFREZZA for the delivery of insulin in Type 1 and Type 2 diabetic patients. The simplistic description of AFREZZA is that it's an insulin inhaler that could render insulin injections obsolete in the future.

MNKD presented its clinical trials data to an FDA Advisory Panel in April and that panel overwhelmingly recommended AFREZZA for FDA approval. The FDA calendar currently has AFREZZA scheduled for review on July 15th. MannKind and its investors have a lot at stake pending the FDA approval in July.

A full report on MNKD that includes risk factors, industry review, financial position, potential revenues, and review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link:

http://bit.ly/MNKD-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.    

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs